Treatment for female hyposexual desire disorder edges closer

Palatin Technologies has applied to the US Food and Drug Administration for marketing approval for melanocortin-receptor-4 agonist bremelanotide for the treatment of female hyposexual desire disorder.
Palatin says the two 24-week Phase III RECONNECT trials involving over 1200 women – so far unpublished – have …

More details...

Europe agrees measures to stop valproate use during pregnancy

European states are set to ban valproate for treating migraine or bipolar disorder and to limit its use to treat epilepsy as a last resort. Women or girls of childbearing age for whom it is prescribed will be required to join a pregnancy prevention programme …

More details...

Developments in treatments for MS

Roche’s monoclonal antibody ocrelizumab (Ocrevus) has become the first medicine licensed for the treatment of primary progressive multiple sclerosis (PPMS) following EU approval in January. It is also licensed for relapsing MS (RMS), an indication that now has a wide range of treatment options.
Ocrelizumab selectively …

More details...

Adjunctive treatment fails to help Alzheimer’s disease

The 5-hydroxytryptamine-6 receptor antagonist idalopirdine did not improve cognition in people with mild to moderate Alzheimer’s disease when added to treatment with a cholinesterase inhibitor, a series of Phase III trials has shown (JAMA 2018;319:130-142). The three 6-month trials involved a total of 2,525 patients …

More details...

Government consults on children’s mental health

The Government published proposals to improve mental health support for children and young people at the beginning of December 2017. Its Green Paper, Transforming children and young people’s mental health provision, ‘focuses on earlier intervention and prevention particularly in or linked to schools and colleges’ …

More details...

Consensus statement calls for better treatment for personality disorder

The mental health system ‘isn’t working as it needs to work’ for people diagnosed with personality disorder, according to a consensus statement from organisations such as Mind, the British Psychological Society, the Centre for Mental Health and the Royal College of General Practitioners.
Shining lights in …

More details...

Children’s mental health services good but variable, CQC says

‘Too many children and young people have a poor experience of care and some are simply unable to access timely and appropriate support’, the Care Quality Commission concludes in its Review of children and young people’s mental health services (www.cqc.org.uk).
The report, the first to emerge …

More details...

EMA to restrict daclizumab use for MS

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has recommended that provisional measures to restrict the use of daclizumab (Zinbryta) to treat relapsing forms of multiple sclerosis should be strengthened and made permanent (www.ema.europa.eu). Treatment should now be limited to patients who …

More details...

Compulsory Treatment in the Community, if so, on what basis?

A request for help from psychiatrists and all community mental health practitioners.
The Dutch government is introducing new mental health legislation, which will controversially allow for compulsory treatment to be used in the community and in patient’s homes. 
To try to understand the issues better, the Vincent …

More details...

Antidepressant adherence not related to prescriber status

There is minimal variation in adherence to antidepressant therapy between patients treated by a psychiatrist and those treated by a GP, a US study shows (J Clin Psychiatry 2017;10.4088/JCP.16m11324).
Analysis of electronic health records and insurance claims for Washington, Idaho, Minnesota, Colorado, Hawaii and California identified …

More details...

Web design and marketing agency Leamington Spa